Vertex (VRTX) Slumps on VX-809 Data Presentation
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Join SI Premium – FREE
Vertex Pharmaceuticals (Nasdaq: VRTX) shares are slumping as data for VX-809 is being presented. Vertex didn't see significant change in patient weight gain, with the 56-day study not being long enough.
Additionally, according to a biotech follower, investors shouldn't expect tight correlation between sweat chloride reduction and FEV1. Sweat chloride "just a biomarker."
Data is being presented by lead study investigator Michael P. Boyle, M.D., F.C.C.P. For more, click here.
Shares are down 6 percent Thursday.
Additionally, according to a biotech follower, investors shouldn't expect tight correlation between sweat chloride reduction and FEV1. Sweat chloride "just a biomarker."
Data is being presented by lead study investigator Michael P. Boyle, M.D., F.C.C.P. For more, click here.
Shares are down 6 percent Thursday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA expands Casgevy approval to children as young as 2
- FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
- FDA approves Casgevy gene therapy for sickle cell in children 2+
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
